Major players from across the UK’s health and life sciences sector have responded to the Autumn Budget delivered by Labour ...

Novartis’ Scemblix (asciminib) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat a ...

AbbVie has announced that it will be acquiring Aliada Therapeutics for $1.4bn, marking a notable boost to its neuroscience ...

The Northern Hemisphere flu season is fast approaching, bringing with it a multitude of challenges for respiratory clinical ...

Generative AI platforms are revolutionizing drug discovery, driving significant biopharma dealmaking by enabling the design ...

Every year, the medical community recognizes the month of November as Clostridioides difficile (C. diff) Awareness month. C.

Knowing this, it amazes me how many pharmaceutical organisations of all sizes are missing the mark on key areas of launch ...

Pharma companion apps are transforming healthcare by offering support beyond traditional treatments, enhancing patient ...

Johnson & Johnson (J&J) has shared positive results from a late-stage study of its dual-acting IL-23 inhibitor Tremfya ...

BeiGene’s Tevimbra (tislelizumab) has been recommended by the European Medicines Agency’s human medicines committee as a first-line treatment for gastric and oesophageal cancer patients. The Committee ...

Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat resectable non-small cell ...

Merck & Co – known as MSD outside the US and Canada – has acquired Yale University oncology spinout Modifi Biosciences in a deal worth $1.3bn. The agreement gives Merck access to preclinical compounds ...